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Abstract
Glioblastoma multiforme (GBM) is the most common and the most aggressive form of primary brain tumor. Jak2 is a non-
receptor tyrosine kinase that is involved in proliferative signaling through its association with various cell surface receptors.
Hyperactive Jak2 signaling has been implicated in numerous hematological disorders as well as in various solid tumors
including GBM. Our lab has developed a Jak2 small molecule inhibitor known as G6. It exhibits potent efficacy in vitro and in
several in vivo models of Jak2-mediated hematological disease. Here, we hypothesized that G6 would inhibit the pathogenic
growth of GBM cells expressing hyperactive Jak2. To test this, we screened several GBM cell lines and found that T98G cells
express readily detectable levels of active Jak2. We found that G6 treatment of these cells reduced the phosphorylation of
Jak2 and STAT3, in a dose-dependent manner. In addition, G6 treatment reduced the migratory potential, invasive potential,
clonogenic growth potential, and overall viability of these cells. The effect of G6 was due to its direct suppression of Jak2
function and not via off-target kinases, as these effects were recapitulated in T98G cells that received Jak2 specific shRNA.
G6 also significantly increased the levels of caspase-dependent apoptosis in T98G cells, when compared to cells that were
treated with vehicle control. Lastly, when T98G cells were injected into nude mice, G6 treatment significantly reduced tumor
volume and this was concomitant with significantly decreased levels of phospho-Jak2 and phospho-STAT3 within the
tumors themselves. Furthermore, tumors harvested from mice that received G6 had significantly less vimentin protein levels
when compared to tumors from mice that received vehicle control solution. Overall, these combined in vitro and in vivo
results indicate that G6 may be a viable therapeutic option against GBM exhibiting hyperactivation of Jak2.
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Introduction
Glioblastoma mulitforme (GBM) is the most common and most
aggressive form of primary brain tumor. The median survival is 14
months after optimal therapy such as surgical resection, radiation
therapy, and/or chemotherapy. The most commonly used
chemotherapeutic agent for GBM is temozolomide, which acts
as a DNA alkylating agent. However, temozolomide resistance in a
large number of GBM patients has prompted the development of
alternate therapies [1]. Recently, some of the molecular mecha-
nisms involved in GBM pathogenesis have been identified and
these discoveries have led to the development of molecular
targeted therapies. Pathways that have been targeted to date
include VEGF, EGFR, PDGF, PI3K, Akt, and mTOR [2].
Although many of these therapies have shown promising pre-
clinical efficacy, the clinical outcomes have not been highly
successful thus far [3–4].
Vimentin is a type III intermediate filamentous protein. Along
with actin and tubulin, it comprises the cytoskeleton of the cell and
hence plays an important role in anchoring various organelles
within the cytosol. It is highly expressed in mesenchymal cells and
serves as an extremely reliable marker for indicating epithelial-to-
mesenchymal transition [5]. Vimentin is overexpressed in a
number of tumors including those of the brain, breast, lung, and
prostate. Furthermore, within these cancers, vimentin expression
correlates with accelerated tumor growth, increased metastatic
potential, and poorer prognosis [6]. Within the brain, vimentin
expression is observed in all grades of astrocytomas [7]. In
addition, a recent report identified a positive correlation between
glioma grade and vimentin expression and these same authors
found that temozolomide resistance is associated with an up-
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regulation of vimentin [8]. When taken together, these results
indicate that vimentin is both a marker of brain tumor
pathogenesis and a predictor of chemotherapy resistance.
Recently, there has been increasing interest in the role of Jak/
STAT signaling in GBM and the use of Jak/STAT small molecule
inhibitors for the treatment of these tumors. Specifically, in 2007,
constitutive phosphorylation of Jak2 was found in the GL15
glioblastoma cell line, and treatment with tyrphostin AG490, a
pan tyrosine kinase inhibitor, was shown to induce cell cycle arrest
in these cells [9]. More recently, studies have demonstrated the
efficacy of more specific Jak2 kinase inhibitors in both cell culture
and animal models of GBM [10,11]. Along these lines of
investigation, our laboratory has spent the past several years
identifying Jak2 specific small molecule inhibitors. One compound
in particular, G6, has shown exceptional in vitro and ex vivo
therapeutic efficacy [12,13]. In addition, it has been highly
efficacious in three mouse models of Jak2-mediated hematological
disease [14–16].
Here, we hypothesized that G6 treatment would reduce the
tumorigenic potential of GBM cells that exhibit constitutive Jak2
signaling. To test this, we first screened GBM cell lines in order to
identify those with increased levels of phospho-Jak2. We found
that the T98G cell line expressed readily detectable levels of the
protein and furthermore, the existing Jak2 was hyper-active. We
found that G6 treatment of these cells significantly reduced the
tumorigenic potential both in vitro and in vivo including
significant reductions in vimentin protein levels within tumors
that were harvested from G6 treated mice. When taken together,
our data indicate Jak2 inhibitors in general, and G6 in particular,
may be viable therapeutic options against GBM exhibiting
constitutive Jak2 signaling.
Materials and Methods
Cell Lines
T98G glioblastoma cells were originally obtained from ATCC
and kindly provided to us by Dr. Jeffrey Harrison (University of
Florida). T98G cells were maintained in MEM supplemented with
10% FBS, 10 U/ml penicillin, 10 mg/ml streptomycin, and 2 mM
L-glutamine at 37uC and 5% CO2.
Cell Proliferation Assay
T98G cells were plated in 96-well plates and treated with the
indicated concentrations of G6 for 72 hours. Cell viability was
determined using the MTS colorimetric assay (Promega) accord-
ing to the manufacturer’s protocol.
Colony Formation Assay
T98G cells were plated in 100 mm dishes at a density of 200
cells per dish and were cultured for 24 hours in the presence or
absence of G6. The drug was then removed, and cells were
cultured for an additional nine days. Cells were then washed with
PBS, fixed in 90% methanol, stained with crystal violet, and the
numbers of colonies were counted.
Western Blotting
Cells were lysed in RIPA buffer (20 mM Tris pH 7.5, 10%
glycerol, 1% Triton X-100, 1% deoxycholic acid, 0.1% SDS,
2.5 mM EDTA, 50 mM NaF, 10 mM Na4P2O7, 4 mM benza-
midine, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4,
and 10 mg/mL aprotinin) and protein concentration was deter-
mined using a Bradford assay (BioRad). Approximately 30 mg of
soluble protein was separated by SDS-PAGE and transferred onto
nitrocellulose membranes. Membranes were blocked at room
temperature for 1 hour with 5% milk in TBS-T and incubated
with primary antibodies overnight at 4uC. The following primary
antibodies were used: pY1007/p1008-Jak2 at 1:300 (Invitrogen),
total Jak2 at 1:1000 (Millipore/Invitrogen), pY705-STAT3 at
1:300 (Santa Cruz), total STAT3 at 1:1000 (Santa Cruz), vimentin
at 1:2000 (Abcam), Caspase-3 at 1:500 (Cell Signaling), and b-
actin at 1:500 (Cell Signaling). Secondary antibodies were applied
for 1 hour at room temperature. Anti-rabbit and anti-mouse
secondary antibodies were used at 1:4000 (GE Healthcare) and
bands were detected via reaction with an enhanced chemilumi-
nescent substrate (Perkin Elmer).
Cell Migration and Invasion Assays
For scratch assays, cells were plated on 4-well chamber slides,
grown to confluency, and treated with G6 for 24 hours. The drug
was then removed, a scratch was made, and migration into the
scratch area was monitored 24 and 48 hours later. For cell
migration assays, 56104 T98G cells were plated in 24-well
migration inserts (PET membrane with 8 mm pores, BD Biosci-
ences). Cells were plated in the top chamber in serum-free MEM
and the bottom chamber was filled with serum-containing MEM.
Cell migration was analyzed 24 hours later. Non-migrating cells
were removed from the top of the chamber using a cotton swab,
and migrated cells were stained with crystal violet and counted.
The cells were counted at 10X magnification, using two random
fields per chamber well. For cell invasion assays, 56104 T98G cells
were plated in 24-well inserts coated with matrigel (BD
Biosciences). The top chamber contained cells in serum-free
MEM and the bottom chamber contained complete MEM. Cell
invasion was analyzed after 48 hours. The cells were counted at
10X magnification, using two random fields per chamber well.
Lentiviral shRNA-Mediated Jak2 Knockdown
HEK293T cells were transfected with Jak2 shRNA constructs
(pool of Thermo catalog numbers RHS3979-9571807, RHS3979-
9571808, RHS3979-9571809, RHS3979-9571810, and
RHS3979-9571811) or a non-targeting shRNA construct (Ad-
dGene plasmid 1864) along with packaging and envelope vectors
(psPAX2 and pMD2.G). Lipofectamine (Invitrogen) was used as
the transfection reagent. Approximately 40 hours post-transfec-
tion, culture media containing virus was collected and supple-
mented with polybrene, sterile filtered, and applied to T98G cells.
A second round of infection was performed 24 hours later.
Infected cells were identified by puromycin selection and used for
subsequent experiments.
Apoptosis Assays
For TUNEL staining, cells were plated on 4-well chamber slides
and treated with G6 for 48 hours. TUNEL staining was
performed as previously described [17].
T98G Xenografts in Nude Mice
All procedures were approved by the Institutional Animal Care
and Use Committee at the University of Florida. T98G cells are
known to have a relatively weak in vivo tumorigenic growth
potential, even in immunocompromised animals [18,19]. For this
reason, 20 female athymic nude mice were flank injected with
56106 T98G cells in 150 ml of a 1:1 mixture of RPMI media and
Matrigel (BD Biosciences). Tumors were measured using an
external caliper and volume was calculated by the formula 4p/
36(length/2)6(width/2)2 as previously described [18]. After 90
days of growth, only nine mice had tumors with a volume that was
.50 mm3. These nine animals were randomly assigned to one of
Jak2 Inhibition and Glioblastoma
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two groups; vehicle control (n = 4) or G6 (n = 5). The beginning
tumor volumes for the two groups were 101+/218 mm3 and
112+/217 mm3, respectively. Mice then began receiving daily
intra-peritoneal injections of either vehicle control solution
(DMSO) or 10 mg/kg/day of G6 and tumor volumes were
measured approximately every fifth day. After 35 consecutive days
of treatment, the mice were euthanized and the tumors were
resected for subsequent analyses.
Apoptotic Gene Profile Analysis of Tumor Sections
RNA was isolated from each freshly harvested tumor using the
RNeasy Mini Kit (QIAGEN). RNase-free DNase was used to
eliminate DNA contamination. cDNA was synthesized from 2 mg
RNA using the high capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Real-time PCR was carried out in a
Multicolor Real-Time PCR Detection System using TaqMan
gene expression assays (Applied Biosystems). All PCR amplifica-
tions were performed in triplicate. Parallel measurements of b-
actin were also done as an internal control for normalization
purposes.
Histological Analysis of Tumors
Tumors were fixed in buffered formalin, paraffin embedded,
and sectioned at 4 mm. Sections were then stained with either
hematoxylin & eosin or Masson’s trichrome. Images were
examined for a number of characteristics including morphology,
cellularity, and fibrosis. Tumor sections were also subjected to
anti-phospho-Jak2, anti-phospho-STAT3, anti-Ki-67, and anti-
vimentin immuno-histochemical (IHC) analyses. The numbers of
positive stained cells were determined via the ScanScope software
system (Aperio).
Statistical Analysis
All results were expressed as mean +/2 SEM. Statistical
comparisons were done using Student’s t test or a repeated-
measures ANOVA for multiple comparisons. Data were consid-
ered to be significantly different when p,0.05.
Results
G6 Reduces Jak2 and STAT3 Phosphorylation in T98G
Cells
Expression of active Jak2 and/or STAT3 has been observed in
a number of immortalized glioblastoma cell lines and primary cells
[5–7]. Here, we initially examined expression of Jak2 protein in
three glioblastoma cell lines; namely, A172, U87MG, and T98G.
Using Western blot analysis, we found that while all three cell lines
expressed readily detectable levels of total Jak2 protein, only in the
T98G cell line was that protein active, as indicated by the high
levels of phospho-Jak2 (Figure 1A). Based on these initial screening
results, we selected the T98G cell line for further experiments in
testing the hypothesis that Jak2 inhibitors are efficacious against
Jak2-dependent GBM tumorigenesis.
We next examined the effects of G6 treatment on Jak2 and
STAT3 phosphorylation in T98G cells. For this, cells were treated
for 24 hours at the indicated concentrations and we found that G6
caused a dose-dependent decrease in Jak2 and STAT3 phosphor-
ylation levels (Figure 1B). The phosphorylation levels of these two
proteins were then quantified by densitometry and normalized to
total protein levels (Figures 1C and 1D). These results indicate that
G6 effectively inhibits Jak2/STAT3 signaling in T98G cells. We
also examined the effects of the pan-tyrosine kinase inhibitor,
AG490, which is commonly used as a Jak2 inhibitor in cell-based
assays. We found that AG490 modestly inhibited Jak2 phosphor-
ylation, but in a manner that was not entirely dose-dependent,
even at 100 mM (Figure S1). Thus, in addition to being a more
specific Jak2 inhibitor, G6 appears to either have greater potency
than AG490 or it inhibits different off-target kinases, whose
inhibition may cooperate with Jak2 inhibition to elicit the effects
observed with G6 treatment.
G6 Inhibits Cell Proliferation and Colony Formation in
T98G Cells
We next wanted to determine if the G6-dependent inhibition of
Jak2 phosphorylation in T98G cells would correlate with a
reduction of cell viability and/or colony formation potential. For
measurements of cell viability, T98G cells were treated with
increasing concentrations of G6 for the indicated times and
viability was determined by the colorimetric MTS assay. We found
that G6 caused both a dose- and time-dependent decrease in
T98G cell viability (Figures 2A and 2B). For colony formation
assays, cells were treated with the indicated concentrations of G6
for 24 hours, washed extensively with PBS, and the numbers of
colonies were determined nine days later. We found that G6
caused a dose-dependent decrease in the ability of T98G cells to
form colonies (Figure 2C). Collectively, the data in Figure 2
indicate that G6 reduces both the cell viability and the colony
forming potential of T98G cells in vitro.
G6 Reduces the Migratory and Invasive Potential of T98G
Cells
The ability to migrate into and invade surrounding tissue is an
important clinical characteristic of glioblastoma cells. Here, we
wanted to determine if G6 treatment could reduce the migratory
and/or invasive potential of T98G cells. We first used a scratch
assay to examine cell migration. Cells were grown to confluency
and treated with G6 for 24 hours, at which point the drug was
removed, and a scratch was made. We found that G6 treatment
markedly reduced the migration of cells back into the scratch area
(Figure 3A). For a more quantitative examination of cell migra-
tion, we used a trans-well migration/invasion assay. Specifically,
cells were treated with G6 for 24 hours and then plated in 24-well
chamber inserts. Inserts were either uncoated for migration assays,
or coated with matrigel for the invasion assays. The numbers of
migrating and invading cells were then determined. We found that
when compared to cells that were treated with DMSO control
solution, G6 treatment reduced cell migration and invasion and
this effect was dose-dependent (Figures 3B, 3C, 3D, and 3E).
These results indicate that G6 is effective at significantly reducing
both the migratory and invasive potential of T98G glioblastoma
cells.
Lentivirus-Mediated Knockdown of Jak2 Reduces
Migratory and Invasive Potential of T98G Cells
We next wanted to determine if the effects of G6 on the
migratory and invasive potentials of T98G cells could be
reproduced by specifically knocking down Jak2. The main goal
of these experiments was to determine if the effects of G6 could be
attributed directly to the inhibition of Jak2 signaling, rather than to
any off target effects of the drug on other proteins. Here, we used
lentiviral-mediated shRNA to silence Jak2 in T98G cells. We
found that Jak2 mRNA expression was reduced by approximately
80% in Jak2 knockdown cells, when compared to cells that were
transfected with control scrambled shRNA (Figure 4A). We also
found that Jak2 protein expression was similarly reduced in these
cells (Figures 4B and 4C). After puromycin selection, cells were
plated in uncoated or matrigel-coated 24-well chamber inserts and
Jak2 Inhibition and Glioblastoma
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cell migration and invasion were examined. We found that Jak2
knockdown significantly reduced the migratory (Figures 4D and
4E) and invasive (Figures 4F and 4G) potentials of these cells.
When taken together, we conclude that Jak2 plays an important
role in maintaining the migratory and invasive potential of these
cells and the ability of G6 to reduce T98G cell migration and
invasion is via its Jak2 inhibiting property.
G6 Induces Caspase-Dependent Apoptosis in T98G Cells
We have previously shown that G6 induces strong caspase-
dependent apoptosis in human erythroleukemia cells [14].
Therefore, we wanted to determine if this mechanism is conserved
in similarly treated T98G cells. Here, T98G cells were treated with
increasing concentrations of G6 for 48 hours and the levels of
apoptosis were subsequently determined via TUNEL staining. We
found that G6 treatment caused a dose-dependent increase in the
number of TUNEL-positive cells and this was statistically
significant (Figures 5A and 5B). In order to determine the specific
mechanism of apoptosis in these cells, we examined the level of
caspase 3/7 activity after treatment with G6. We found that G6
caused a significant increase in the level of caspase-3/7 activity
when compared with DMSO control treated cells (Figure 5C).
During apoptosis, full length caspase-3 is cleaved from its inactive
precursor into its active form. The disappearance of full length
caspase-3 typically correlates with an increase in caspase activity
and thus, indicates an increase in apoptotic signaling. We
examined the expression of caspase-3 by Western blot and found
that G6 treatment caused a dose-dependent decrease in the levels
of full-length caspase-3 (Figure 5D). Overall, these results indicate
that G6 reduces T98G cell viability by inducing caspase-
dependent apoptosis.
G6 Reduces Tumor Volume in T98G Xenografts and This
Is Coincident with Increased Expression of BIM and BAX
We next tested the ability of G6 to reduce the tumorigenic
potential of T98G cells in vivo. Specifically, T98G cells were
placed in a semi-solid matrix and injected subcutaneously into the
flanks of nude mice. After 90 days of growth, mice began receiving
daily intraperitoneal injections of either DMSO or 10 mg/kg G6.
Tumor volumes were then measured about once every five days
for the ensuing 35 days, at which time the mice were euthanized.
Figure 6A shows tumor volumes plotted as a function of both
treatment and time. Overall, the mice that received G6 had
significantly smaller tumor volumes when compared to those that
received DMSO. Given the ability of G6 to induce apoptosis of
T98G cells (Figure 5), a section of each tumor was immediately
Figure 1. G6 reduces Jak2 and STAT3 phosphorylation in T98G cells. A) Expression of phospho-Jak2 in three glioblastoma cell lines. c2A+
Jak2 cell lysates were used as a Jak2-positive control. Shown is one of three representative blots. B) T98G cells were treated with the indicated
concentrations of G6 for 24 hours and examined for Jak2 and STAT3 phosphorylation levels by Western blot. Shown is one of three representative
blots for each protein. Quantification of the Jak2 (C) and STAT3 (D) phosphorylation levels (n = 3 for each). *, p,0.05 relative to DMSO control treated
cells as determined by ANOVA.
doi:10.1371/journal.pone.0105568.g001
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subjected to gene profile analysis for several different apoptotic
genes. We found that while the anti-apoptotic Bcl-xL and pro-
apoptotic Mcl-1 were not significantly different between the two
treatment groups, mice that received G6 had significantly higher
levels of pro-apoptotic BIM and BAX (Figure 6B). When taken
together, these data indicate that G6 treatment reduces tumor
volume, in part, via increased expression of BIM and BAX.
Reduced Tumor Volumes Correlate with Decreased
Levels of phospho-Jak2 and phospho-STAT3
Post mortem analyses continued with histological and immuno-
histochemical examinations of the tumors. Examinations of the
tumors after H&E staining found marked nuclear atypia and
numerous mitotic figures in the tumors that were harvested from
the DMSO treated mice, and this appeared to be reduced in the
tumors that came from the G6 treated group (Figure 7). Immuno-
histochemical analysis indicated that G6 reduced the levels of
phospho-Jak2 and phospho-Stat3 within the tumors by an average
of 58.8% and 48.6%, respectively (Figure 7). In addition to
inducing discernible caspase-dependent apoptosis (Figure 5), G6
can also reduce cell proliferation [14]. To determine whether G6
had an effect on cell proliferation within the T98G derived tumors,
sections were stained for Ki-67, a nuclear protein whose levels
correlate directly with cell proliferation [20,21]. We found that G6
reduced the levels of Ki-67 immuno-staining by 27% and this was
statistically significant (Figure 7). Lastly, the levels of tumor fibrosis
were determined via Masson’s Trichrome staining. On average,
the levels of fibrosis in the tumors that were harvested from G6
treated mice were .2-fold higher when compared to tumors that
were taken from DMSO treated mice (Figure 7). When taken
together, the data in Figure 7 indicate that treatment with G6
results in tumors that have decreased pJak2, decreased pSTAT3,
decreased Ki-67, and increased fibrosis, when compared to vehicle
control treated tumors.
G6 Reduces the Levels of Vimentin Protein within T98G-
Derived Tumors
As noted above, a recent report identified a direct correlation
between glioma grade and vimentin expression as well as a direct
correlation between increased vimentin expression and temozolo-
mide resistance [8]. Interestingly, we have previously shown that
within hematopoietic cells that have constitutive Jak2 signaling,
G6 not only suppresses the aberrant Jak2 signaling, but it also
decreases vimentin protein levels within these same cells, and the
Figure 2. G6 treatment reduces T98G cell viability and clonogenic growth potential. A) T98G cells were treated with increasing
concentrations of G6 for 72 hours and cell viability was measured by MTS assay. Each point was measured in triplicate. Shown is one of three
representative results. The 10 mM and 30 mM conditions were significantly lower (p,0.05) when compared to cells treated with DMSO alone as
determined by ANOVA. B) T98G cells were treated with G6 for the indicated times and concentrations. Cell viability was then measured via MTS. Each
point was measured in triplicate. Shown is one of three representative results. **, p,0.01 relative to DMSO treated cells as determined by ANOVA. C)
T98G cells were treated with G6 for 24 hours at the indicated concentrations, washed, and seeded in 100 mm dishes. Cells were grown for nine
additional days, stained with crystal violet, and colonies were then counted. Shown is the average of four representative results. *, p,0.05 relative to
DMSO treated cells as determined by ANOVA.
doi:10.1371/journal.pone.0105568.g002
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loss of vimentin protein per se, is sufficient to cause tumor cell
death [(22]. Here, we sought to measure vimentin protein levels
within the tumors so that we could determine if G6 similarly
promotes the loss of vimentin protein within GBM. For this, a
portion of each tumor was first subjected to Western blot analysis
with anti-vimentin antibody (Figure 8A). We found that tumors
taken from G6 treated mice had significantly reduced vimentin
protein levels when compared to tumors that came from DMSO
treated mice and this difference was statistically significant
(Figure 8B). Next, a portion of each tumor was subjected to
anti-vimentin immuno-histochemistry. For the tumors that came
from G6 treated mice, we found that vimentin staining was
reduced when compared to tumors that came from DMSO
treated mice (Figure 8C) and this difference was significant
(Figure 8D). Lastly, we have previously shown that in the absence
of any drug treatment, vimentin is largely distributed over the
cytoplasm [22]. However, when G6 is added to cells, not only does
it decrease vimentin protein levels, but for the protein that remains
in the cell, it redistributes in an irregular pattern around the
perinuclear region of the cell [22]. To determine if this was
similarly conserved in GBM, tumor sections were subjected to
anti-vimentin immuno-fluorescence and counterstained with
DAPI. For the tumors that came from DMSO treated mice,
vimentin was generally expressed in the cytoplasm (Figure 8E).
However, for the tumors that came from G6 treated mice, the
vimentin protein formed noticeable aggregates in the perinuclear
region of some cells (Figure 8E). As such, the cumulative data
indicate that administration of G6 to mice reduces the levels of
vimentin protein within T98G-derived xenografts. Furthermore,
G6 promotes atypical aggregation of the vimentin protein around
the perinuclear region of some of the cells.
Discussion
Here, we have identified the Jak2 small molecule inhibitor G6
as a potential therapy for Jak2-dependent glioblastoma. We found
that the T98G glioblastoma cell line expresses a high level of active
Jak2 (ie, pJak2), and that treatment with G6 reduced Jak2/STAT3
phosphorylation in a dose-dependent manner. We also found that
this correlated with reductions in cell viability, colony forming
Figure 3. G6 reduces migratory and invasive potential of T98G cells. A) Cells were treated with G6 for 24 hours at the indicated
concentrations, washed, and a scratch was made. Cell migration was monitored 24 and 48 hours later. Shown is one of three representative results. B)
Cells were treated with G6 for 24 hours at the indicated concentrations, washed, and plated in un-coated 24-well inserts. Cell migration was
examined by crystal violet stain after 24 hours. Shown is one of three representative results. C) Cells were treated with G6 for 24 hours at the
indicated concentrations and plated in matrigel-coated 24-well inserts. Cell invasion was examined by crystal violet stain after 48 hours. Shown is one
of three representative results. D) Quantification (n = 3) of migrating cells. *, p,0.05 vs. DMSO control treated cells as determined by ANOVA. E)
Quantification (n = 3) of invading cells. Scale bars represent either 100 mm (A) or 50 mm (B and C). *, p,0.05 vs. DMSO control treated cells as
determined by ANOVA.
doi:10.1371/journal.pone.0105568.g003
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abilities, cell migration, and cell invasion properties. The ability of
G6 to promote these beneficial effects appears to be via its ability
to inhibit Jak2, rather than via any off target effects as some of
these results were recapitulated via the specific knock down of Jak2
by shRNA. Lastly, when examined in vivo, we found that G6
treatment significantly reduced tumor volumes. Furthermore,
tumors that were harvested from G6 treated mice exhibited
increased apoptosis, decreased pJak2, decreased pSTAT3, de-
creased Ki-67, increased fibrosis, and decreased vimentin levels
when compared to vehicle control treated mice. Collectively, these
results indicate that G6 has discernible therapeutic efficacy in
glioblastoma cells that express active Jak2.
In the initial studies examining the role of Jak2 in glioblastoma,
the tyrphostin compound, AG490, was used to block Jak2
activation. These studies demonstrated that inhibition of tyrosine
kinases in general, and Jak2 in particular, could impact the
viability and invasive properties of GBM cells [9,23]. Our results
contained herein provide additional evidence of a role for Jak2
signaling in glioblastoma cells and the potential application of Jak2
inhibitors for GBM therapy. Interestingly however, in a set of
studies where we examined the effect of G6 on U87MG cells, a
GBM cell line where Jak2 is not hyper-phosphorylated, G6 was
not as efficacious as it was in T98G cells (Figure S2). Along similar
lines, in a very recent Phase I clinical study, the Jak2 inhibitor
AZD1480 was given as a monotherapy to 38 patients with
advanced solid tumors, with none being GBM. In addition, no
consideration was given as to the status of the Jak/STAT signaling
pathway in these patients. The authors found that the drug
provided no observable clinical benefit, and along with a number
of reported serious adverse events, this has led to an abandonment
of the study [24]. Thus, the success of Jak2 inhibitor therapy for
GBM, or any solid tumor for that matter, may first require the
identification of those that have dys-regulated Jak2 signaling.
The role of Jak2 signaling in glioblastoma tumors has only
recently been investigated, so the clinical significance of Jak2
inhibition is still unclear. However, recent studies have demon-
strated that Jak/STAT signaling is an important contributor to
tumorigenicity of human glioma cells, and that specific inhibition
of this pathway reduces tumorigenic potential of these cells [25–
26]. One of these studies utilized derivatives of AG490 to
effectively target brain tumor stem cells (BTSCs) in a xenograft
model [26]. In addition, another recent study showed that Jak2/
Figure 4. Jak2 knockdown reduces the migratory and invasive potential of T98G cells. A) Jak2 mRNA expression was examined by qRT-
PCR. Each sample was measured in triplicate. Shown is one of three representative results. B) Jak2 protein expression was examined by Western blot.
C) Quantification of Jak2 protein expression from three independent blots. D) Cells were plated in 24-well inserts and migration was monitored after
24 hours. E) Quantification of migrating cells from four independent experiments. F) Cells were plated in matrigel-coated 24-well inserts and invasion
was monitored after 48 hours. G) Quantification of invading cells from four independent experiments. Scale bars represent either 50 mm (D and 10X
F) or 100 mm (4X F) *, p,0.05 relative to scrambled shRNA as determined by Student’s t test.
doi:10.1371/journal.pone.0105568.g004
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STAT3 signaling is essential in the migration, invasion, and tumor
progression of EGFRvIII glioblastoma cell lines [27]. Moreover,
this study revealed that only Jak2 inhibition, not STAT3 nor
EGFR knockdown, was able to suppress the migratory and
invasive phenotype of these EGFR mutant cell lines. In another
study, it was found that an allosteric Jak2 inhibitor had greater
efficacy against EGFR vIII-expressing cell lines than wild-type
EGFR cells [28]. EGFRvIII mutations are observed in a large
subset of glioblastoma tumors, including 20% of newly diagnosed
glioblastoma patients in a recent study [29] and up to 67% in
previous patient cohorts [30]. Given the high occurrence of this
mutation and the selectivity of Jak2 inhibitors for EGFRvIII-
positive glioma cells, stratifying patients by EGFR mutation status
may be an important factor in assigning Jak2 inhibitor therapy.
In order for G6 to have a potential role in the treatment of
GBM, it must cross the blood-brain barrier and reach therapeutic
concentrations within this organ. To determine if this was possible,
naı¨ve mice were intravenously injected with G6 and drug
concentrations were subsequently determined in the brain. We
found that G6 could readily cross the blood-brain barrier and
could maintain IC50 inhibitory values for at least six hours after
drug administration (unpublished observations). As such, these
results indicate that G6 can potentially target GBM or other
central nervous system derived diseases.
With respect to the tumorigenic growth potential of T98G cells,
we found that G6 treatment reduced pJak2, pSTAT3, cell
proliferation, cell migration, cell invasion, and induced apoptosis.
While these events are all highly desirable for any chemothera-
peutic agent, a clear yet less understood phenomenon that we
repeatedly observed was that G6 treatment lead to increased levels
of fibrosis within the tumors themselves. Interestingly, examination
of the lungs, livers, and kidneys from these same animals found no
fibrosis whatsoever, suggesting that the increased fibrosis in the G6
treated mice was a tumor-specific event. Consistent with this
observation that G6 does not promote host organ fibrosis is a
previous work where we reported that a 30 day administration of
G6 into C57BL/6 mice did not produce any histological
abnormalities, such as fibrosis, within the hearts, brains, kidneys,
Figure 5. G6 induces caspase-dependent apoptosis in T98G cells. A) Cells were treated with G6 for 48 hours and apoptosis was examined by
TUNEL immunofluorescence. Shown is one of three independent results. Scale bar = 50 mm. B) Quantification (n = 3) of the percentage of TUNEL-
positive cells. *, p,0.05 vs. DMSO control treated cells as determined by ANOVA. C) Cells were treated for the indicated times with a 10 mM
concentration of G6 and Caspase 3/7 activity was measured by a luminescent assay at the indicated times. Each point was measured in triplicate and
shown is one of three independent experiments. A significant difference (*, p,0.05) was noted between the 72 hour time points as determined by
ANOVA. D) Cells were treated with G6 for 48 hours and full length Caspase-3 expression was measured by Western blot. Shown is one of two
representative blots.
doi:10.1371/journal.pone.0105568.g005
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or lungs of the treated animals [14]. However, fibrosis within host
tissues and tumor tissue is quite different and it is still unclear
whether increased tumor fibrosis is advantageous or deleterious to
the survival of the animal [31,32]. What is clear, however, is that
the tumors from G6 treated mice had noticeably increased levels
of collagen deposition when compared to mice that received
DMSO. This is an area of current investigation as we are trying to
determine whether the G6-mediated tumor fibrosis is due to the
expansion of fibroblasts subsequent to the death of T98G cells
within the tumor, alterations in the epithelial-mesenchymal
transition of cells by G6, fibrotic re-modeling that is subsequent
to the resolution of an inflammatory response within the tumor, or
yet another mechanism. Additionally, it will be of interest to see if
other Jak2 inhibitors produce a similar type fibrotic effect in GBM
tumor models.
Another significant component of this work is the observation
that G6 treatment reduces the levels of vimentin within the T98G-
derived tumors. Within solid tumors in general, vimentin
expression correlates with accelerated tumor growth, increased
metastatic potential, and poorer prognosis [6]. Within brain
tumors in particular, vimentin expression also correlates with
temozolomide resistance, a frontline therapy for the treatment of
GBM [8]. Presumably, a treatment that reduces vimentin
expression, such as G6, may result in decreased tumor growth,
decreased metastatic potential, increased sensitivity to temozolo-
mide, and improved patient prognosis. Thus, in addition to being
used as a monotherapy as we demonstrated here, G6 may have
potential as an adjunct therapy with other agents such as
temozolomide for the treatment of GBM. It has recently been
suggested that GBM tumors can be subcategorized into three
classes based on expression levels of intermediate filament
proteins, including vimentin [33]. Therefore, stratification of
patients based on vimentin expression and Jak2 activation status
may eventually allow for maximal therapeutic efficacy of Jak2
inhibitor therapy in GBM.
Cancers in general and gliomas in particular are characterized
by a number of cellular perturbations including increased cell
division, avoidance of apoptosis, enhanced clonogenic growth
potentials, enhanced migratory potentials, enhanced invasive
potentials, and an ability to promote tumor vascularization.
Chemotherapeutic agents generally target 1–2 of these properties
and this of course provides the rational basis for combination drug
therapies for the treatment of cancer. In the case of G6 however,
we found that it was efficacious for a multitude of cellular
responses including proliferation, apoptosis, migration, invasion,
clonogenic growth, and perhaps even a de-vascularization effect.
Figure 6. G6 reduces tumor volume in T98G xenografts and this is coincident with increased expression of BIM and BAX. A) After
establishment of the tumors, mice began receiving daily injections of either DMSO (n= 4) or 10 mg/kg G6 (n = 5) at Day 0. Tumor volumes are plotted
as a function of both treatment condition and time. B) Average mRNA levels of various apoptotic markers taken from the tumors. *, p,0.05, **, p,
0.01.
doi:10.1371/journal.pone.0105568.g006
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These pleiotropic effects of G6 are consistent with the known roles
of Jak2 in these same biological processes [34]. Thus, because of its
role in a number of processes that are critical for tumor
maintenance and growth, Jak2 inhibitor therapy may be more
efficacious than other targeted therapies for tumors in which Jak2
signaling is dys-regulated.
In summary, we found that the T98G cell line expressed readily
detectable levels of active Jak2 protein. We found that G6
treatment of these cells significantly reduced their tumorigenic
potential both in vitro and in vivo. When taken together, our data
indicate that Jak2 inhibitors in general, and G6 in particular, may
be viable therapeutic options against GBM exhibiting constitutive
Jak2 signaling.
Supporting Information
Figure S1 Treatment of T98G Cells with AG490. T98G
cells were seeded in 100 mm dishes and treated with the indicated
concentrations of AG490 for 24 hours. Soluble protein lysates
Figure 7. Reduced Tumor Volumes Correlate with Decreased Levels of phospho-Jak2 and phospho-STAT3. Shown are representative
tumor sections, from the same nine mice described in Figure 6, after they were fixed, sectioned, and stained. For the H&E stained sections, mitotic
cells are indicated by the green arrowheads. For pJak2, pSTAT3, Ki-67, and trichrome, the relative intensity of staining was quantified via relative pixel
counting. Average pixel counts were then plotted as a function treatment group. The objective lens magnifications were either 50X (H&E) or 40X
(pJak2, pSTAT3, Ki-67, and Trichrome). Scale bar = 50 mm. *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0105568.g007
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were then prepared and Jak2 was immuno-precipitated from the
lysates via the addition of anti-Jak2 antibody. After separation by
SDS-PAGE, the samples were Western blotted with either anti-
pJak2 (top) or anti-Jak2 (bottom) antibody.
(TIF)
Figure S2 Effect of G6 on U87MG Cell Viability. U87MG
cells were seeded in 96-well plates and then treated with the
indicated concentrations of G6. 72 hours later, cell viability was
determined via MTS. Each point was measured in triplicate.
Shown are the average number of cells (mean +/2 SD)
normalized to cells that received DMSO alone.
(TIF)
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